Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) news covers a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals. The company’s updates frequently highlight progress across its crofelemer programs, regulatory interactions, and partnerships.
Investors following JAGX news can expect coverage of developments related to Mytesi, Napo Pharmaceuticals’ FDA-approved crofelemer product for noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy, as well as Jaguar’s broader intestinal failure program targeting rare disorders such as short bowel syndrome with intestinal failure (SBS-IF) and microvillus inclusion disease (MVID). News items often describe clinical trial milestones, proof-of-concept data on reductions in parenteral support, and discussions with regulators about potential expedited approval pathways for ultrarare pediatric indications.
On the animal health side, Jaguar news includes information about Canalevia-CA1, the company’s conditionally approved crofelemer-based prescription drug for chemotherapy-induced diarrhea in dogs, along with regulatory grants, conditional approval renewals, and studies designed to support full approval. Updates may also address efforts to obtain guidance from the European Medicines Agency for Canalevia in general diarrhea in dogs.
Corporate and capital markets announcements are another key component of JAGX news. These can include securities purchase agreements, royalty interest amendments, PIPE financings, preferred stock exchanges, and at-the-market offering amendments, as disclosed in Form 8-K filings. Conference presentations, investor summit appearances, and summaries of stockholder meeting results also appear in the company’s news flow.
For investors and observers, the Jaguar Health news page provides a centralized view of clinical, regulatory, commercial, and financing developments that shape the company’s strategy in plant-based gastrointestinal therapeutics for both human and veterinary medicine.
Jaguar Health reported a net revenue of approximately $2.6 million for the first quarter of 2022, marking a 24% increase from the previous quarter and a 112% year-over-year growth. This revenue boost is attributed to the transition to a closed network of specialty pharmacies. The company is focused on ongoing clinical trials for crofelemer, particularly for cancer therapy-related diarrhea, with enrollment expected to complete in the first half of 2023. Future milestones include proof-of-concept studies for short bowel syndrome and congenital diarrheal disorders in 2022-2023.
Jaguar Health, Inc. (NASDAQ:JAGX) announced the grant of 50,000 restricted stock units (RSUs) to Mark Johnson, its newly appointed Senior Vice President of Product Development, effective May 6, 2022. The RSUs will fully vest on the one-year anniversary of his hire, contingent on his continued service with the company. The compensation, approved by the Compensation Committee, serves as an inducement for his acceptance of the position. Jaguar, a commercial-stage pharmaceuticals company, focuses on developing plant-based medications for gastrointestinal distress in humans and animals.
Jaguar Health, Inc. (NASDAQ:JAGX) announced an investor webcast on May 10, 2022, at 8:30 AM ET to discuss first-quarter 2022 financial results and corporate updates. The company plans to file its Earnings Report on Form 10-Q for the quarter ending March 31, 2022. The previous release incorrectly stated the date as March 10. Jaguar Health focuses on developing plant-based, non-opioid pharmaceuticals for gastrointestinal distress in humans and animals. For more details, register here.
Jaguar Health, Inc. (NASDAQ:JAGX) announced an investor webcast on May 10, 2022, at 8:30 AM Eastern Time to discuss first-quarter 2022 financial results and corporate updates. The earnings report will be filed on May 10, 2022, on Form 10-Q. Jaguar focuses on developing plant-based, non-opioid medicines for gastrointestinal issues in both humans and animals. The company is known for its drug candidate, crofelemer, which is currently involved in a pivotal Phase 3 clinical trial for diarrhea in cancer patients receiving targeted therapy.
Jaguar Health (NASDAQ:JAGX) has filed the final regulatory section with the FDA for conditional approval of its oral plant-based drug Canalevia to treat exercise-induced diarrhea (EID) in dogs. Canalevia would be the first treatment for EID in dogs to gain any form of FDA approval. Following conditional approval for chemotherapy-induced diarrhea (CID) in December 2021, Jaguar expects EID approval by Q4 2022. The FDA has confirmed the completeness of three of the four required technical sections for this application.
Jaguar Health (NASDAQ:JAGX) announced the commercial availability of Canalevia-CA1, the first FDA-approved treatment for chemotherapy-induced diarrhea (CID) in dogs. Following its conditional approval on December 21, 2021, this oral medication is now accessible through leading veterinary distributors in the U.S. The company highlights the unmet need for such a treatment, as over half of surveyed veterinarians noted CID disrupts cancer treatment in dogs. Canalevia-CA1, using the plant-based active ingredient crofelemer, aims to enhance dogs' comfort during chemotherapy.
Jaguar Health, Inc. (NASDAQ:JAGX) announced that its CEO, Lisa Conte, will present at NobleCon18 on April 21, 2022, at 11:00 AM Eastern at the Hard Rock Hotel & Casino in Hollywood, Florida. Attendees can meet management during a breakout session at 10:00 AM. Registration for this investor conference is free via the provided link. A video of the presentation will be available the next day on Noble Capital Markets' website and archived for 90 days. Jaguar focuses on sustainable, plant-based medicines for gastrointestinal issues.
Jaguar Health (NASDAQ:JAGX) has announced the replenishment of its New Employee Inducement Award Plan with 471,833 shares of common stock, effective June 16, 2020. This addition is on top of 500,000 shares registered previously on May 28, 2021. The plan aims to grant equity awards to new hires or former employees, serving as an inducement for their employment as per Nasdaq Listing Rule 5635(c)(4).
Jaguar focuses on developing plant-based, non-opioid pharmaceuticals for gastrointestinal issues.
Jaguar Health (NASDAQ:JAGX) announces a dinner event for U.S. veterinary oncologists on April 12, 2022, in Puerto Vallarta, Mexico, coinciding with the Veterinary Cancer Society (VCS) Mid-Year Conference. The dinner will focus on chemotherapy-induced diarrhea (CID) treatment in dogs, featuring a private chef and entertainment. Canalevia-CA1 (crofelemer), the first FDA conditionally approved treatment for CID in dogs, will be showcased at the conference. The VCS Mid-Year Conference runs from April 9-12, 2022, at the Marriott Puerto Vallarta Resort & Spa.
Jaguar Health, Inc. has appointed Pravin Chaturvedi, PhD, as Chief Scientific Officer and Chair of the Scientific Advisory Board. Dr. Chaturvedi, with over 30 years in the pharmaceutical industry, will lead two key crofelemer pipeline development activities over the next 12-15 months. These include the Phase 3 OnTarget trial for cancer therapy-related diarrhea and collaborations for rare diseases like short bowel syndrome. Both initiatives aim to expand patient access and enhance Jaguar's market position, with completion expected soon.